Gary Charles Robb - Jun 3, 2024 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Signature
/s/ Joseph Douglas Lyon, as attorney-in-fact for Gary Charles Robb.
Stock symbol
CORT
Transactions as of
Jun 3, 2024
Transactions value $
$35,060
Form type
4
Date filed
6/5/2024, 09:19 PM
Previous filing
May 30, 2024
Next filing
Jun 6, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CORT Common Stock Tax liability -$21.8K -724 -3.58% $30.17 19.5K Jun 3, 2024 Direct F1, F2, F3
transaction CORT Common Stock Award $56.9K +1.82K +9.33% $31.30 21.3K Jun 3, 2024 Direct F3, F4, F5
transaction CORT Common Stock Award $0 +1.82K +8.54% $0.00 23.1K Jun 3, 2024 Direct F3, F6
holding CORT Common Stock 7.7K Jun 3, 2024 Custodial Account for Child F7
holding CORT Common Stock 8.7K Jun 3, 2024 Custodial Account for Child F7
holding CORT Common Stock 8.7K Jun 3, 2024 Custodial Account for Child F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
F2 The closing price on May 31, 2024 was used to calculate the withholding obligation.
F3 Includes 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 638 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, and 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F4 The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 3, 2024.
F5 In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
F6 Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
F7 These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.